Agenus(US:AGEN) Prnewswire·2024-10-17 09:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Agenus Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its immuno-oncology products, botensilimab and balstilimab, during the class period from January 23, 2023, to July 17, 2024 [1][2]. Group 1 - The class action alleges that the combination therapy of botensilimab and balstilimab was less effective than represented, leading to overstated clinical results and regulatory prospects [1]. - Shareholders who purchased shares during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment, which is not required for recovery [1]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is November 5, 2024 [2]. Group 2 - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].